Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Philips NV
  6. News
  7. Summary
    PHIA   NL0000009538

PHILIPS NV

(PHIA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Philips : Koninklijke Philips N.V., - Philips delivers Q3 sales of EUR 4.2 billion, with a 7.6% comparable sales decline due to headwinds; income from continuing operations increases to EUR 442 million, and Adjusted EBITA margin amounts t

10/18/2021 | 04:32am EST

Q3 2021

Quarterly report

Philips delivers Q3 sales of EUR 4.2 billion, with a 7.6% comparable sales decline due to headwinds; income from continuing operations increases to EUR 442 million, and Adjusted EBITA margin amounts to 12.3%.

Philips sees continued strong demand driving double-digit order intake growth in Q3.

Amsterdam, October 18, 2021

Third-quarter highlights

  • Group sales totaled EUR 4.2 billion, reflecting a 7.6% comparable sales decline due to headwinds caused by global supply chain challenges and Sleep & Respiratory Care recall consequences
  • Comparable order intake increased 47%; order intake increased 17% excluding the impact of a partial ventilator order cancellation in Q3 2020
  • Income from continuing operations increased to EUR 442 million, compared to EUR 279 million in Q3 2020
  • Adjusted EBITA of EUR 512 million, or 12.3% of sales, compared to EUR 684 million, or 15.5% of sales, in Q3 2020
  • Operating cash flow of EUR 256 million, compared to EUR 575 million in Q3 2020
  • Domestic Appliances divestment was completed as planned, resulting in a EUR 2.5 billion gain after tax and transaction-related costs; reported in Discontinued Operations

Frans van Houten, CEO

"I am pleased with the strong double-digit comparable order intake growth in the third quarter, driven by both the Diagnosis & Treatment businesses and Connected Care businesses. Our strategy and portfolio are highly relevant to our customers, as we help them transform the delivery of care along the health continuum. Building on this strength, we have signed an additional 19 long-term strategic partnerships with hospitals across the world, including a 10-year partnership with Baptist Health in the US to provide patient monitoring solutions and standardize care across the network.

We recorded EUR 4.2 billion sales in the quarter, with a 7.6% comparable sales decline on the back of 10% comparable sales growth last year. This quarter's sales were impacted unfavorably by intensified global supply chain issues, such as the shortage of electronic components, and the anticipated revenue consequences of the sleep recall, as we are prioritizing the remediation of affected devices in use by patients. The Adjusted EBITA margin was 12.3%.

The repair and replacement program related to the sleep recall notification is under way in the US and several other markets. I am conscious of the impact this is having on patients and care givers, and we are doing everything we can to deliver a solution as fast as possible.

We successfully completed the sale of the Domestic Appliances business, resulting in a gain of EUR 2.5 billion. With this, we concluded our major divestments, allowing us to focus fully on extending our leadership in health technology and continuing our transformation into a solutions company.

Quarterly Report 2021 - Q3

1

Looking ahead, we continue to see uncertainty related to COVID-19. Supply chain volatility has intensified globally, which already led to longer lead times to convert our strong order book to revenue in the third quarter, and we expect this headwind to continue in the fourth quarter. Therefore, we now expect to deliver low-single-digit comparable sales growth with a modest Adjusted EBITA margin improvement for the full year 2021. Based on our strong customer demand and growing order book, we expect to resume our growth and margin expansion trajectory in 2022 as we work through the headwinds."

Business segment performance

The Diagnosis & Treatment businesses recorded 10% comparable sales growth, with double-digit growth in Image-Guided Therapy and high-single-digit growth in Diagnostic Imaging and Ultrasound. Comparable order intake increased 15%, with double-digit growth across Image-Guided Therapy, Diagnostic Imaging and Ultrasound, reflecting Philips' very competitive portfolio and positive market conditions. The Adjusted EBITA margin increased to 14.2%, mainly driven by sales growth and productivity measures.

The Connected Care businesses' comparable sales decreased 39%, following the high COVID-19-generated demand in Q3 2020 and a double-digit decline in Sleep & Respiratory Care in Q3 2021 due to the sleep recall notification. Comparable order intake increased 21%, excluding the impact of a partial ventilator order cancellation in Q3 2020. Hospital Patient Monitoring orders grew 20% in Q3 2021, building on 22% order intake growth last year, driven by a structural increase in adoption of patient care management solutions in both high- and low-acuity care settings in the hospital. The Adjusted EBITA margin amounted to 6.2%, mainly due to the decline in sales.

The Personal Health businesses' comparable sales were in line with Q3 2020, as sales across the businesses were impacted by phasing, with 33% comparable sales growth in the previous quarter. The underlying customer demand for the new product introductions in Personal Care, Oral Healthcare and Mother & Child Care remains robust. The Adjusted EBITA margin increased to 15.9%, mainly driven by productivity measures.

In Other, sales increased by EUR 74 million and Adjusted EBITA increased to EUR 13 million, mainly driven by phasing of IP royalty settlements.

Philips' ongoing focus on innovation and partnerships resulted in the following highlights in the quarter:

  • Philips provided the Yili Chuanxin Oncology hospital in Xinjiang, a newly established top-tier private hospital in China, with an Oncology solution to address the hospital's clinical needs in screening, precision diagnosis, targeted treatment and rehabilitation of cancer patients. The solution includes IntelliSpace Digital Pathology and the Ingenia 3.0T MR, IQon Spectral CT, Incisive CT and CT Big Bore imaging systems, combined with IntelliSpace Portal for advanced visualization and analysis.
  • As part of Philips' 10-year partnership with Rutherford Health to open multiple Community Diagnostic Centers in England, the first center was opened in Taunton, for which Philips provided innovative diagnostic imaging systems, including Ingenia Ambition MR combined with Ambient Experience, which allows patients to control and personalize the imaging environment.
  • As a pioneer in spectral CT diagnostics, Philips has enabled its customers to benefit from a reduction in follow-up scans, increased certainty in lesion characterization, and reduced time to diagnosis. Building on many years of experience with IQon Spectral CT, Philips' new Spectral CT 7500 is attracting strong customer demand. For example, the University Medical Center Utrecht in the Netherlands installed two Spectral CT systems, with the aim of providing greater confidence in mainstream clinical diagnosis - for all patients and in all exams.
  • Underlining the company's leading role in digital pathology, Philips partnered with Healius Pathology, one of Australia's leading providers of private medical laboratory and pathology services, to deploy a multi-site digital pathology solution across Healius' National Pathology Network using Philips' industry-leading IntelliSite Pathology Solution.
  • Building on Philips' leadership in image-guided therapy solutions in cardiology, the company is further strengthening its position in fast- growing adjacencies such as neurology and oncology. For example, US-based Piedmont Health equipped its neurosurgical operating rooms with a specialized version of Philips Azurion for the treatment of stroke. Philips also announced positive results of a clinical study aimed at setting a new standard of safety and accuracy in the diagnosis of small peripheral lung lesions using Philips Lung suite.
  • Underlining Philips' strategy to deliver locally relevant solutions, the company launched several oral healthcare innovations targeting multiple price points in China, including two new electric toothbrushes. In addition, Philips launched its professional teeth whitening offering Zoom in China through a local partnership with LinkedCare, one of the largest dental solution providers in the Chinese dental market.
  • Philips launched two new HealthSuite informatics solutions which are scalable across the enterprise, to support its customers in achieving the Quadruple Aim of healthcare: Patient Flow Capacity Suite, a solution that helps hospitals manage the complete patient journey, and Acute Care Telehealth, which builds on Philips' successful Tele-ICU solutions.
  • Philips' recently acquired Capsule business continued to add new device drivers to its Medical Device Information Platform, which will be integrated with HealthSuite. With more than 1,000 unique types of medical devices capable of integrating with the platform, customers can connect more devices to advance health systems' digital transformation with intelligent, vendor-agnostic tools that turn complex data streams into actionable insights.

Sleep and respiratory care field action update

On June 14, 2021, Philips initiated a voluntary recall notification in the US/field safety notice outside the US for certain sleep and respiratory care products to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices. Following the substantial ramp-up of its production, service and repair capacity, the repair and

Quarterly Report 2021 - Q3

2

replacement program in the US and several other markets is under way. To date, Philips has produced a total of approximately 750,000 repair kits and replacement devices, of which more than 250,000 have reached customers.

As disclosed in its Q2 2021 report, Philips is a defendant in a number of consumer class action lawsuits from users of the affected devices and a number of individual personal injury claims. Given the uncertain nature and timing of the relevant events and potential associated liabilities, if any, the company is unable to reliably estimate the financial effect of these matters.

Cost savings

In the third quarter, productivity savings amounted to EUR 73 million, of which procurement savings amounting to EUR 34 million, and savings of EUR 39 million delivered by overhead and other programs.

Capital allocation

Philips is currently executing two share buyback programs of EUR 1.5 billion each for capital reduction purposes. The program that was initiated in the first quarter of 2019 is nearing completion and is expected to result in the cancellation of approximately 20 million shares in December 2021. Under the share buyback program that was announced on July 26, 2021, Philips entered into a number of forward transactions in the third quarter, covering approximately half of the program, with settlement dates in 2022, 2023 and 2024. The remainder of the program will be executed through open market purchases by an intermediary, with a significant part taking place in Q4 2021. Further details on both programs can be found here.

Conference call and audio webcast

Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.

Quarterly Report 2021 - Q3

3

Philips performance

Key data in millions of EUR unless otherwise stated

Q3 20201)

Q3 2021

Sales

4,411

4,156

Nominal sales growth

6%

(6)%

Comparable sales growth2)

10%

(8)%

Comparable order intake3)

(18)%

47%

Income from operations

396

358

as a % of sales

9.0%

8.6%

Financial expenses, net

(26)

(5)

Investments in associates, net of income taxes

(5)

(3)

Income tax

(86)

92

Income from continuing operations

279

442

Discontinued operations, net of income taxes

61

2,538

Net income

340

2,980

Earnings per common share (EPS)

Income from continuing operations

0.30

0.47

attributable to shareholders4) (in EUR) -

diluted

Adjusted income from continuing operations

0.50

0.40

attributable to shareholders4) (in EUR) -

diluted2)

Net income attributable to shareholders4) per

0.37

3.24

common share (in EUR) - diluted

EBITA2)

456

426

as a % of sales

10.3%

10.2%

Adjusted EBITA2)

684

512

as a % of sales

15.5%

12.3%

Adjusted EBITDA2)

924

739

as a % of sales

20.9%

17.8%

  1. Comparative figures in this report have been restated, refer to 'Presentation' in Forward- looking statements and other important information.
  2. Non-IFRSfinancial measure. Refer to Reconciliation of non-IFRSinformation.
  3. Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2020.
  4. Shareholders refers to shareholders of Koninklijke Philips N.V.
  • Comparable sales declined by 8% due to headwinds caused by global supply chain challenges and Sleep & Respiratory Care recall consequences. The Diagnosis & Treatment businesses recorded double-digit comparable sales growth and the Personal Health businesses flat growth, which were more than offset by a double- digit comparable sales decline in the Connected Care businesses.
  • Comparable order intake increased by 47%. Excluding the partial cancellation of a ventilator contract in Q3 2020, comparable order intake grew by 17%. The Connected Care businesses and Diagnosis & Treatment businesses recorded double-digit comparable order intake growth.
  • Adjusted EBITA decreased by EUR 172 million and the margin decreased by 320 basis points compared to Q3 2020, due to the decline in sales, partly offset by productivity measures.
  • Restructuring, acquisition-related and other charges amounted to EUR 87 million, compared to EUR 229 million in Q3 2020. Q3 2020 included a EUR 57 million onerous contract provision and a provision of EUR 38 million related to legal matters.
  • Financial income and expenses resulted in an expense of EUR 5 million, compared to an expense of EUR 26 million in Q3 2020. Q3 2021 includes gains on the value of our minority participations and higher interest income.
  • Income tax decreased by EUR 178 million year-on-year, mainly due to the impact from the recognition of tax assets due to a business transfer.
  • Net income from discontinued operations increased by EUR 2,477 million year-on-year, mainly driven by the result on the sale of the Domestic Appliances business.
  • Net income increased by EUR 2,640 million, mainly driven by the result on the sale of the Domestic Appliances business.

Sales per geographic cluster in millions of EUR unless otherwise stated

% change

Q3 2020

Q3 2021

nominal

comparable1)

Western Europe

972

870

(10)%

(11)%

North America

1,770

1,670

(6)%

(10)%

Other mature

425

383

(10)%

(8)%

geographies

Total mature

3,167

2,924

(8)%

(10)%

geographies

1,231

(1)%

(2)%

Growth geographies

1,244

Philips Group

4,411

4,156

(6)%

(8)%

  1. Non-IFRSfinancial measure. Refer to Reconciliation of non-IFRSinformation.

Amounts may not add up due to rounding

  • Comparable sales declined by 8% due to headwinds caused by global supply chain challenges and Sleep & Respiratory Care recall consequences. Sales in growth geographies decreased by 2% on a comparable basis, with double-digit growth in Central & Eastern Europe and India, which was more than offset by a double-digit decline in Latin America and Middle East & Turkey. In mature geographies, sales decreased by 10% on a comparable basis, due to Western Europe and North America, partly offset by mid- single-digit growth in Japan.

Quarterly Report 2021 - Q3

4

Cash and cash equivalents balance in millions of EUR

Net cash flows from operating activities decreased to EUR 256

Q3 2020

Q3 2021

million, due to phasing and consumption of provisions.

Beginning cash balance

2,294

1,019

Treasury shares transactions includes share repurchases for capital

Free cash flow1)

359

45

reduction purposes and employee stock purchase plans.

256

Changes in debt mainly includes the repayments of commercial

Net cash flows from operating activities

575

(210)

paper amounting to EUR 300 million and two bilateral loans

Net capital expenditures

(216)

totaling EUR 500 million.

Other cash flows from investing activities

(280)

(40)

Dividend paid to shareholders includes a EUR 73 million tax paid

Treasury share transactions

(22)

(84)

on dividend.

Changes in debt

(36)

(909)

Net cash flows from discontinued operations includes the net

Dividend paid to shareholders

(1)

(73)

cash proceeds received on the sale of the Domestic Appliances

Other cash flow items

(12)

8

business.

Net cash flows from discontinued operations

187

3,860

Ending cash balance

2,490

3,827

  1. Non-IFRSfinancial measure. Refer to Reconciliation of non-IFRSinformation.

Composition of net debt to group equity1) in millions of EUR unless otherwise stated

June 30, 2021

September 30, 2021

Long-term debt

5,882

6,623

Short-term debt

1,949

1,011

Total debt

7,831

7,635

Cash and cash equivalents

1,003

3,827

Net debt

6,827

3,808

Shareholders' equity

11,952

14,561

Non-controlling interests

34

42

Group equity

11,987

14,602

Net debt : group equity

36:64

21:79

ratio1)

  1. Non-IFRSfinancial measure. Refer to Reconciliation of non-IFRSinformation.
  • Net debt: group equity ratio improved in Q3 2021, mainly driven by the net cash proceeds received and gain on the sale of the Domestic Appliances business.

Quarterly Report 2021 - Q3

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Royal Philips NV published this content on 18 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2021 08:31:01 UTC.


© Publicnow 2021
All news about PHILIPS NV
05:23aRoyal Philips' Surgical Navigation Solution Successfully Treats Two Patients In Spain, ..
MT
04:48aPHILIPS NV : Deutsche Bank sticks Neutral
MD
04:00aPhilips expands Augmented Reality Surgical Navigation – ClarifEye – to two ..
AQ
11/29Philips extends AI-enabled CT imaging portfolio at RSNA 2021
AQ
11/29Periodic update on transaction details related to Philips' share repurchases
AQ
11/28Philips spotlights new and enhanced vendor-neutral radiology workflow solutions and sca..
AQ
11/26PHILIPS : Periodic update on transaction details related to Philips' share repurchases
PU
11/24Royal Philips Enters Collaborations to Merge Medical Imaging Platforms
MT
11/24Philips collaborates with leading institutes to bring its breakthrough spectral CT imag..
AQ
11/23Philips launches new AI-enabled MR portfolio of smart diagnostic systems, optimized wor..
AQ
More news
Analyst Recommendations on PHILIPS NV
More recommendations
Financials
Sales 2021 17 535 M 19 897 M 19 897 M
Net income 2021 3 567 M 4 047 M 4 047 M
Net Debt 2021 4 199 M 4 765 M 4 765 M
P/E ratio 2021 7,10x
Yield 2021 2,91%
Capitalization 27 998 M 31 557 M 31 769 M
EV / Sales 2021 1,84x
EV / Sales 2022 1,71x
Nbr of Employees 77 084
Free-Float 99,4%
Chart PHILIPS NV
Duration : Period :
Philips NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHILIPS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 31,20 €
Average target price 45,15 €
Spread / Average Target 44,7%
EPS Revisions
Managers and Directors
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Feike Sijbesma Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PHILIPS NV-28.75%31 557
THERMO FISHER SCIENTIFIC35.86%249 365
DANAHER CORPORATION44.79%229 837
INTUITIVE SURGICAL, INC.18.94%115 866
SIEMENS HEALTHINEERS AG53.22%81 326
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.-15.86%68 292